KV Acquires Particle and Coating Technologies
This article was originally published in The Pink Sheet Daily
Executive Summary
PCT’s Proprietary coating technologies will augment KV’s development of both generics and branded products, firm says.
You may also be interested in...
KV Gets ANDA Approval For Two Strengths Of AstraZeneca’s Toprol-XL
KV believes it has 180-day exclusivity for the 100 mg and 200 mg strengths of the hypertension treatment.
Vivus Sells EvaMist Rights To KV For $150 Million
Vivus CEO tells “The Pink Sheet” DAILY that sale of estrogen product will allow firm to focus on obesity candidate Qnexa.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee